Second malignancies in Hodgkin's disease: a complication of certain forms of treatment.

Abstract

Summary and conclusions A total of 764 patients with Hodgkin's disease treated with radiotherapy (RT)

Acute Lymphoblastic Leukaemia after Radiotherapy and Adjuvant Chemotherapy (CMF) for Breast Cancer

“…This is almost certainly related to the mutagenic effect of radiotherapy and chemotherapy [1,4,8,13,15], often used in combination in the modern therapeutic procedures.…”

Hodgkin's cell lines: Characteristics and possible pathogenetic implications

“…Secondary neoplasias are the most hazardous consequence of intensive combined treatment modalities (radio-chemo-therapy) at the moment and amount up to 5-10 per cent of all initially diagnosed Hodgkin patients (Borum, 1980;Coltman and Dixon, 1982;Valagussa et al, 1980). The incidence of acute myeloid or myelo-monocytoid leukemia is 130 times higher in Hodgkin's patients than in normal individuals (Glicksman et al, 1982).…”

Acute non‐lymphocytic leukemia (ANLL) following treatment with dacarbazine for malignant melanoma

“…In fact, Valagussa et a1 found no second malignancies in 104 patients they treated for Hodgkin disease on the ABVD program [7]. Zarrabi and Rosner do cite one of acute myeloblastic leukemia in a patient with melanoma receiving dacarbazine, but the short latency period of 6 to 12 months makes it unlikely that dacarbazine was the causative factor [8].…”